Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0TJNBS
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Adcitmer
|
|||||
| Synonyms |
Trastuzumab-pyr-c-Val-Cit-PABC-MMAE
Click to Show/Hide
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Merkel cell carcinoma [ICD11:2C34]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
3.89
|
|||||
| Structure |
|
|||||
| Antibody Name |
Trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Pyridino-caproic-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
TTZ were site-specifically conjugated with a potent antimitotic, MMAE, using McSAF Inside technology.
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.